Form 4 for YCBD cbdMD, Inc.
Accepted 2022-05-18 00:00:00 ET · period of report 2022-05-16 · accession 0001654954-22-007147 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-05-18 | 2022-05-16 | YCBD | MacDermott Kevin | Pres | A - Grant | — | +125.0K | 126.0K | +12,500% | — |
| D | 2022-05-18 | 2022-05-16 | YCBD | MacDermott Kevin | Pres | A - Grant | — | +405.0K | 405.0K | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-16 | A | A | 125,000 | — | 126,000 | D | — | — | (F1) Represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of four non-employee directors. The restricted stock units were issued under the 2021 Equity Compensation Plan as partial compensation to the Reporting Person for his services as the Issuer's President beginning May 16, 2022. |
| 2 | Derivative | Common Stock (Right to Buy) | 2022-05-16 | A | A | 405,000 | — | 405,000 | D | $0.84 · — to 2022-05-16 | 405,000 Common Stock | (F2) The stock options were granted under the 2021 Equity Compensation Plan as compensation to the Reporting Person as the Issuer's President beginning May 16, 2022. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of three non-employee directors. The options vest annually in three equal increments on May 15, 2023, May 15, 2024, and May 15, 2025. |